Navigation Links
Data on novel IL-1 inhibitor protein for topical treatment of dry eye disease published
Date:2/18/2013

Cambridge, MA, February xx, 2013 Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases. In the paper entitled "Design of a superior cytokine antagonist for topical ophthalmic use," the scientists, including drug developers from Eleven Biotherapeutics and collaborators from Howard Hughes Medical Institute and Stanford University School of Medicine, describe how EBI-005 was designed to specifically bind more tightly to its target than IL-1Ra providing a dramatic increase in potency in vivo. EBI-005 was also shown to have substantially greater stability, potentially providing the convenience of room temperature storage.

"To date, blocking of IL-1 has only taken the conventional form of proteins as injectable therapies." said Thomas M. Barnes, Vice President of Discovery at Eleven Biotherapeutics and lead author of the PNAS publication. "These published data reflect the basis of our innovative approach to rationally design proteins with ideal therapeutic properties, including the specificity to target and block IL-1 providing localized treatment of ocular diseases through topical administration."

"EBI-005 is unique in that it is rationally designed to be a topically-administered protein with IL-1α and IL-1β blocking capabilities and other ideal pharmacologic and pharmaceutical properties," said Abbie Celniker, PhD, Chief Executive Officer of Eleven Biotherapeutics. "We are currently evaluating the potential of EBI-005 in a multi-center Phase 1b clinical study in patients with dry eye disease and plan to report top line data in the second half of 2013."

Key findings include:

  • EBI-005 binds to its target, IL-1R1, 85-fold more tightly than IL-Ra, translating into a 100-fold increase in potency in vivo.
  • EBI-005 is more thermally stable than IL-1Ra, indicating potential for a room temperature-stable product.
  • EBI-005 has been rationally designed by chimerizing two IL-1 receptor ligands, IL-1β and IL-1Ra, to create an optimized receptor antagonist, for topical ocular administration.
  • As a rationally-designed antagonist, EBI-005 represents a novel approach to therapeutic design that can potentially be exploited for other proteins in the IL-1 and FGF families.


'/>"/>
Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Rutgers team discovers novel approach to stimulate immune cells
3. Novel drug candidates offer new route to controlling inflammation
4. Researchers present new findings for novel pancreatic cancer vaccine
5. Novel biomarkers reveal evidence of radiation exposure
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Study supports urate protection against Parkinsons disease, hints at novel mechanism
8. Novel Natural Sciences Repository Opens Web Portal
9. Novel Anti-Inflammatories May Offer a New Approach for the Treatment of Stroke
10. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
11. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... to the OSEHRA popHealth Community in 2014. It is the culmination ... the Developer Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announced it will co-exhibit with technology partners LG Business Solutions at ATARC ... Metro Center in Washington D.C., will provide education and examination into the mobility ...
(Date:3/27/2017)... ... March 27, 2017 , ... Adding to its ... Journal of Medicine and NEJM Journal Watch, announces the release of NEJM ... by a panel of pediatricians from leading medical centers. The content was then ...
(Date:3/27/2017)... Rock, AR (PRWEB) , ... March 27, 2017 , ... ... CMSA National Board of Directors on June 30, 2017. CMSA’s membership has elected ... In addition to our current Military Advisory position, a new VA Advisory position has ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be ... groin injury, it occurs when the muscles around the pelvis become inflamed. Over ... the lower torso, as well as accompanying tenderness and weakness. Without proper intervention, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
(Date:3/27/2017)...  Twist Bioscience, a company accelerating science and innovation ... raised an additional $33 million. To date, Twist Bioscience ... "It is an exciting time to be leading ... to deliver industry-leading gene volume to our customers, enabling ... Leproust, Ph.D., CEO of Twist Bioscience. "We welcome the ...
(Date:3/27/2017)... , March 27, 2017   Genprex, Inc. , a ... Julien Pham , MD, the Company,s Chief Operating Officer, is ... conferences. Sachs 5th Annual Cancer BioPartnering & Investment ... New York, NY ... BioCentury 24th Annual Future Leaders in Biotech ...
Breaking Medicine Technology: